Scientists discover how to beat resistance to standard leukaemia drug
(Medical Xpress) -- Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell today.
The team carried out the research in CML cells. They showed that drugs currently in early development, called MEK inhibitors, combined with nilotinib (Tasigna) destroyed CML cells after they had stopped responding to imatinib (Glivec), the current standard treatment for CML.
Imatinib and nilotinib kill CML cells by blocking a strong molecular survival signal keeping them alive. The drugs are designed to fit snugly into a protein called BCR-ABL like a key into a lock so as to lock up BCR-ABL and prevent it from triggering the survival signal in the first place.
In some cases BCR-ABL changes its shape and imatinib and nilotinib can no longer fit their key into BCR-ABLs lock. The survival signal remains switched on and these drugs are powerless to turn it off. Survival for these cells means uncontrolled cell growth the root of cancer.
But the scientists revealed that a second set of molecular keys drugs called MEK inhibitors can lock up a protein called MEK, the final checkpoint in the chain of proteins controlling the survival signals. Nilotinib seems to make resistant cancer cells more responsive to the effects of MEK inhibitors and so the combination of treatments killed these resistant cells.
The research suggested that using MEK inhibitors alongside nilotinib would overcome CML resistance to imatinib and nilotinib.
Lead author, Professor Richard Marais from the ICR, said: We are learning more about the molecular locks which have seized up, keeping survival signals turned on in CML cells. This important research shows that drugs currently in development can free these locks to switch off survival signals and destroy cancer cells.
Its exciting to discover that the MEK inhibitors can be used alongside nilotinib to kill CML cells that are no longer responding to imatinib or nilotinib alone. Acquired drug resistance is a significant problem in treating chronic myeloid leukaemia, so were very pleased to have found a potential strategy to overcome this. The next stage is to develop MEK inhibitors further and run clinical trials to see if they can be effective in patients.
There are more than 600 cases of CML diagnosed each year in the UK.
Dr. Julie Sharp, Cancer Research UKs senior science information manager, said: People diagnosed with leukaemia today are four times more likely to survive their disease beyond 10 years as those diagnosed in the early 1970s. And thanks to the generosity of the public weve been able to invest in research, which has been at the heart of this progress.
This important discovery increases our understanding of how leukaemia cells respond to drugs and reveals a potential approach to treat the disease after it has become resistant to current treatments.
More information: Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukaemia. Packer et al, Cancer Cell.
Journal reference: Cancer Cell
Provided by Cancer Research UK
- Can cancer drugs combine forces? Aug 16, 2007 | not rated yet | 0
- Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia Dec 08, 2008 | not rated yet | 0
- Activation of LYN kinase is associated with imatinib-resistance in CML patients Jun 25, 2008 | not rated yet | 0
- Second-line CML drugs evoke faster, better front-line remissions Jun 05, 2010 | not rated yet | 0
- Therapeutic effect of imatinib improved with addition of chloroquine Apr 13, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
8 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...
Cancer 2 hours ago | not rated yet | 0 |
When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...
Cancer 2 hours ago | not rated yet | 0 |
Study leader, Professor John Mathews from the University of Melbourne said this small increase in cancer risk must be weighed against the undoubted benefits from CT scans in diagnosing and monitoring disease.
Cancer 6 hours ago | not rated yet | 0
Cancer survivors are no more likely to stop smoking, cut down on alcohol, or exercise more often than the general population, according to new research published in the British Journal of Cancer today (Wednesday)
Cancer 8 hours ago | not rated yet | 0
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...
Cancer 8 hours ago | not rated yet | 0
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
36 minutes ago | not rated yet | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
15 minutes ago | not rated yet | 0 |
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
9 minutes ago | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
7 minutes ago | not rated yet | 0
What effect does a father's depression have on his young son or daughter? When fathers report a high level of emotional intimacy in their marriage, their children benefit, said a University of Illinois study.
41 minutes ago | not rated yet | 0
Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.
37 minutes ago | not rated yet | 0